התפתחות דרמטית בויטיליגו קראו

By Serena Gordon HealthDay Reporter MONDAY, Feb. 5, 2018 (HealthDay News) -- Doctors have discovered a combination of treatments that can return color to skin that has been lightened by vitiligo -- the skin disease that turned Michael Jackson's skin white. The new therapy includes the oral medication Xeljanz (tofacitinib) -- a drug already approved for use in rheumatoid arthritis patients that dampens the body's immune response -- and ultraviolet-B light therapy. The combination has only been used on two vitiligo patients, but according to a study author, the results have been dramatic. Experts add, however, that the findings need to be duplicated in studies with larger groups of people. The treatment produces "results that are impossible to achieve with common therapies," said Dr. Brett King, an associate professor of dermatology at Yale University School of Medicine. "I think this is a breakthrough in vitiligo treatment," he added. One of King's vitiligo patients, Shahanaj Akter, agreed. "My skin is so much better. I can use make-up and it blends nicely. I am so excited," she said. Akter, 34, first noticed a white patch of skin above her eyebrow on her normally brown skin while she was pregnant in her 20s. That patch grew bigger and bigger, and then white patches showed up on her hands and neck. Vitiligo is a skin condition that causes white patches of skin to appear on various parts of the face and body, according to the Vitiligo Research Foundation (VRF). The disorder can also cause hair to lose its pigment and turn white. The condition can affect people of any race, but is more noticeable in people with darker skin and hair. General vitiligo is believed to be an autoimmune condition, which means the immune system mistakenly attacks pigment-producing cells (melanocytes). The condition affects up to 2 percent of the world's population, according to the VRF. Vitiligo is not contagious. But King said people are often concerned when they see people with vitiligo on their hands. He said patients have told him that cashiers sometimes ask them to put money or credit cards down on the counter so they don't have to touch their hands. "Vitiligo affects the way the world interacts with you. It can be frustrating and embarrassing, and for some, it leads to clinical depression and anxiety," King said. Akter was living in her native country of Bangladesh when her condition first began, and vitiligo carries even more of a stigma there. Some people said unkind things to her. "I cried a lot. I wanted to be my color again," she said. To that end, Akter tried treatment after treatment in Bangladesh and then in the United States. Some therapies caused intolerable side effects, and none brought the results she was hoping for. "It was terrible. I tried so many things," she said. That's when King suggested she try the new combination therapy. At the time of treatment, Akter had white patches on about three-quarters of her face. She also had patches on her neck, chest, forearms, hands and shins. She was given 5 milligrams of tofacitinib twice daily, and full body UV-B light therapy twice weekly. After three months, Akter's face was almost completely free of white patches. About 75 percent of her neck, chest, forearms and shins were re-pigmented with color. Her hands had only minimal freckling. How does this treatment work? Dr. Seemal Desai, a clinical assistant professor of dermatology at the University of Texas Southwestern Medical Center in Dallas, explained it this way: "The immune system is attacking the melanocytes, so they go into hiding. Tofacitinib tells them it's OK to come out of hiding, and the UV light brings them out of hibernation." King and his colleagues also reported on a white man in his 50s who had long-standing vitiligo. He had previously received treatment to remove all pigment so he would be uniformly white. But he still had patches of whiter skin on 90 percent of his face. He also had patches on his torso and arms. After three months of treatment on his face, he had about 50 percent re-pigmentation. After six months, he had about 75 percent re-pigmentation of his face. King was surprised at how effective the treatment was because the man had previously undergone chemical destruction of the pigment cells. Desai said the findings "look promising, and that new treatment options are great." But, he added, this study needs to be replicated in a larger group of people. And he noted that right now, people will likely have a hard time getting reimbursed for tofacitinib because it's not approved for treating vitiligo. He didn't know exact costs but said the drug is quite expensive. Estimates put the drug's price tag at roughly $2,000 a month. Both King and Desai said the drug seems to be well tolerated. King said he doesn't know how long people would need to take the drug, but suspects some would be on it long-term, possibly for life. Details of the cases were published online Jan. 31 in a research letter in the journal JAMA Dermatology. More information Learn more about vitiligo from the American Academy of Dermatology. SOURCES: Brett King, M.D., Ph.D., associate professor, dermatology, Yale University School of Medicine, New Haven, Conn.; Shahanaj Akter, New Haven, Conn.; Seemal Desai, M.D., clinical assistant professor, dermatology, The University of Texas Southwestern Medical Center, Dallas; Jan. 31, 2018, JAMA Dermatology, online Last Updated: Feb 5, 2018 Copyright © 2018 HealthDay. All rights reserved. HealthDay TV Play Promising Vitiligo Treatment

אל תמהר לשמוח , אני מכיר את הסיפור הזה משנת 2015 זוהי תרופה ביולוגית עם תופעות לוואי רציניות כפי שהתגלו בתקופות הניסוי שלה ובכל מקרה התוצאה היא זמנית כמו כל טיפול עם ויטיליגו. אי אפשר לקחת את התרופה ללא הגבלה וכאשר מפסיקים אותה הכל חוזר יותר מכך, ויטיליגו שנמשך זמן רב לא מגיב לטיפול הזה הגם שהתוצאה זמנית. למי שמבין עניין אין כאן משהו דראמטי. ויטיליגו מחלה מקוללת שנשארת לנצח ( בלתי הפיכה ) כל המידע שציינתי פורסם אודות תרופה זו עוד בשנת 2015

התוצאות זמניות כמו כל טיפול אחר בויטיליגו . כחודשיים לאחר הפסקת הטיפול הכל חוזר. מה שקורה זה שהטיפול ( ביולוגי ) מעכב מולקולה מסויימת וביחד עם הקרנות יש שיפור בפיגמנטציה. אבל....התאים אשר החלו לייצר פיגמנט אינם תאי המקור שנהרסו כבר ואינם קיימים יותר. אלו תאים אחרים שנדדו ממקומות אחרים . בקיצור , פגם גנטי לנצח שלא ירופא לעולם ( למי שמבין מושגי רפואה ) הכי מצער שזה תורשתי שממשיך לפגוע בעתיד גם בצאצאים.

כבר ב 2011 התגלו תועות לוואי משמעותיות סרטן שחפת ועוד צרות קשות לתרופה הזו בעת שנעשו מחקרים על דלקת פרקים. הנה קטע מהמאמר של פרופ בן עמי סלע : בחודש אפריל 2011, שלושה ניסוים קליניים ב-phase III, דיווחו על תוצאות חיוביות עם התכשיר באופן שהביא את ה-FDA להעניק לתכשיר "הכשר מזורז", ואכן בנובמבר 2012 אישר ה-FDA שימוש בתכשיר לטיפול בחולי RA בשלבי מחלה מתונים עד מתקדמים, שלא הגיבו היטב לטיפול אחר. יחד עם זאת צורפה לאישור זה אזהרת "Black box", לפיה המטופלים ב- tofacitinib הם בסיכון מוגבר ללקות בהדבקות מזדמנות בשחפת, בסרטן ובלימפומה. על פי אזהרה זו מטופלים אמורים להיבדק לאפשרות של שחפת סמויה לפני תחילת טיפול ב-tofacitinib, ובמקרה של תוצאה חיובית יש להתחיל קודם בטיפול נגד הדבקה זו לפני התחלת הטיפול ב-tofacitinib. אך גם במהלך טיפול בתכשיר האחרון גם באלה שלא נמצאו מודבקים באופן סמוי בחיידק השחפת, יש לנטר מדי פעם לאפשרות של TB. הדבקות נוספות פרט לשחפת עליהן דווח במהלך טיפול עם tofacitinib, כוללות דלקת ריאות, צלוליטיס, הרפס זוסטר, והדבקות של דרכי השתן. בנוסף יש גם דיווחים על מקרים של הדבקות קנדידה של הושט, pneumocystosis, ציטומגלו, והדבקות מזדמנות אחרות.